The side effects of lithium: new systematic review provides toxicity profile


Lithium is a medicine that has been used for over 50 years to treat depression and bipolar disorder. It comes in two forms that are used clinically: lithium carbonate and lithium citrate.

A certain level of the drug is needed in the blood stream for it to be effective, but if the level rises too high patients can experience unpleasant side effects. Blood tests are regularly taken to ensure that patients have a stable and correct level in their blood stream.

A great deal of concern has been expressed over the years about the potential side effects of this treatment and rightly so. However, before now, no systematic toxicity profile of lithium has been published.

A research team from Oxford University have now published a systematic review and meta-analysis that provides us with a reliable answer to the question: is lithium safe for people with mood disorders?

The researchers have conducted a very thorough and systematic search to identify studies that measure the adverse effects of lithium. They screened 5,988 abstracts and included 385 trials in their analysis.

Here’s what they found:

  • Lithium is associated with increased risk of:
    • reduced urinary concentrating ability (the ability of the kidneys to conserve or excrete water appropriately)
    • hypothyroidism (a condition in which the thyroid gland does not make enough thyroid hormone)
    • hyperparathyroidism (excessive production of parathyroid hormone by the parathyroid glands)
    • weight gain
  • There is little evidence for a clinically significant reduction in renal function in most patients, and the risk of end-stage renal failure is low
  • The risk of congenital malformations is uncertain; the balance of risks should be considered before lithium is withdrawn during pregnancy
  • Because of the consistent finding of a high prevalence of hyperparathyroidism, calcium concentrations should be checked before and during treatment.

Lithium toxicity profile: a systematic review and meta-analysis. Rebecca F McKnight BMBCh, Marc Adida PhD, Katie Budge MSc, Sarah Stockton BA, Guy M Goodwin FMedSci, Prof John R Geddes MD. The Lancet – 20 January 2012. DOI: 10.1016/S0140-6736(11)61516-X. [Abstract]

Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Profile photo of Andre Tomlin

Andre Tomlin

André Tomlin is an Information Scientist with 20 years experience working in evidence-based healthcare. He's worked in the NHS, for Oxford University and since 2002 as Managing Director of Minervation Ltd, a consultancy company who do clever digital stuff for charities, universities and the public sector. Most recently André has been the driving force behind the Mental Elf and the National Elf Service; an innovative digital platform that helps professionals keep up to date with simple, clear and engaging summaries of evidence-based research. André is a Trustee at the Centre for Mental Health and an Honorary Research Fellow at University College London Division of Psychiatry. He lives in Bristol, surrounded by dogs, elflings and lots of woodland!

More posts - Website

Follow me here –